Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Monday, March 11, 2019 at 4:00 PM to 4:30 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 20.03.17 in Vol 6, No 3 (2017): March

This paper is in the following e-collection/theme issue:

Works citing "Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility"

According to Crossref, the following articles are citing this article (DOI 10.2196/resprot.7289):

(note that this is only a small subset of citations)

  1. Xu ML, Gabali A, Hsi ED, Fedoriw Y, Vij K, Salama ME, Ramchandren R, O’Malley D, Wick MR, Battistella M, Gru AA. Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis. The American Journal of Surgical Pathology 2020;44(2):e1
    CrossRef
  2. Sharman JP, Wheler JJ, Einhorn L, Dowlati A, Shapiro GI, Hilton J, Burke JM, Siddiqi T, Whiting N, Jalal SI. A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors. Investigational New Drugs 2019;37(4):738
    CrossRef
  3. Nassif S, El-Zaatari ZM, Attieh M, Hijazi M, Fakhreddin N, Aridi T, Boulos F. Lack of expression of ALK and CD30 in breast carcinoma by immunohistochemistry irrespective of tumor characteristics. Medicine 2019;98(32):e16702
    CrossRef
  4. Stillman RC. Clinical Decision Support Tools Improving Cancer Care. Seminars in Oncology Nursing 2018;34(2):158
    CrossRef
  5. Dalton WS, Sullivan D, Ecsedy J, Caligiuri MA. Patient Enrichment for Precision-Based Cancer Clinical Trials: Using Prospective Cohort Surveillance as an Approach to Improve Clinical Trials. Clinical Pharmacology & Therapeutics 2018;104(1):23
    CrossRef